Sign up
ABOS

Acumen Pharmaceuticals Inc (NASDAQ: ABOS)

Healthcare · Biotechnology

$0.19−0.04 (−15.65%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. ABOS fell 15.65% in the Nov 18 session to $0.19, which is 94.2% below its 52-week high of $3.37. Short interest is 12.30% of float with a 0.35% borrow fee. Two active firms cover the stock as of Nov 19, 2026; two active firms with targets average $6.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumOversold

RSI (14) 21.7 (overbought above 70, oversold below 30)

Trend—

—

Short interest12.3% of float

FINRA settlement Oct 30, 2026

ABOS price chart

Price $0.19 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$0.22Nov 18, 2026 session
Previous close
$0.23Nov 17, 2026 close
Day range
$0.19 – $0.22Nov 18, 2026 session
52-week range
$0.19 – $3.37Through Nov 18, 2026
Volume
3.05MNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$15.48M
P/E (TTM)negative earnings —
Forward P/E—
EPS (TTM)−$1.55
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)0.46

Price history

ABOS · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide55High Tide—
Squeeze35Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
2Buy
0Neutral
0Sell
0Strong Sell

Based on 2 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$5.00
Average$6.50
High$8.00

As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellPorter DerrellSell$30.3KForm 4
Insider sellPorter DerrellSell$29.8KForm 4
Insider sellPorter DerrellSell$15.1KForm 4
Insider sellFountain Nathan BSell$14.3KForm 4
Insider sellMeisner Derek MSell$6.8KForm 4
Insider sellMeisner Derek MSell$28.3KForm 4
Insider sellMeisner Derek MSell$8.0KForm 4
Insider sellMeisner Derek MSell$45.3KForm 4
Insider sellMeisner Derek MSell$10.7KForm 4
Insider sellMeisner Derek MSell$1.9KForm 4
All smart-money activity →

News and press releases

All ABOS news →

Company profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with

CEO
Mr. Daniel J. O'Connell M.B.A.
Headquarters
Newton, MA, United States
Employees
60
IPO date
Jul 1, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.